Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TK2 | O00142 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12736937 | 1.00 | TK1 (0.52) | TK1LMNASMN1; SMN2TK2CYP1A2 | |
| SCHEMBL16363404 | 1.00 | TK1 (0.52) | TK1LMNASMN1; SMN2TK2CYP1A2 | |
| SCHEMBL19876156 | 1.00 | TK1 (0.52) | TK1LMNASMN1; SMN2TK2CYP1A2 | |
| SCHEMBL16373946 | 1.00 | TK1 (0.52) | TK1LMNASMN1; SMN2TK2CYP1A2 | |
| SCHEMBL21051291 | 0.92 | TK1 (0.52) | TK1LMNASMN1; SMN2TK2CYP1A2 | |
| SCHEMBL17279676 | 0.87 | TK1 (0.57) | TK1LMNASMN1; SMN2TK2CYP1A2 | |
| SCHEMBL18873431 | 0.87 | TK1 (0.57) | TK1LMNASMN1; SMN2TK2CYP1A2 | |
| SCHEMBL15066132 | 0.87 | TK1 (0.57) | TK1LMNASMN1; SMN2TK2CYP1A2 | |
| SCHEMBL17283457 | 0.87 | TK1 (0.57) | TK1LMNASMN1; SMN2TK2CYP1A2 | |
| SCHEMBL15066131 | 0.87 | TK1 (0.57) | TK1LMNASMN1; SMN2TK2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285635-A1 | METHOD FOR PRODUCING HIGHLY FUNCTIONAL ARTIFICIAL ORGANS USING APTAMERS | KANGSTEM BIOTECH CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| US-20230127087-A1 | GLYPICAN-3-SPECIFIC MODIFIED APTAMER AND USE THEREOF | Aptamer Sciences Inc. (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20200157543-A1 | BIOMOLECULE IMAGING METHOD USING APTAMER | INTEROLIGO CORPORATION (KR) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157543-A1 | BIOMOLECULE IMAGING METHOD USING APTAMER | ERBB2, ERBB3, ERBB4 | TK1 9/4885LMNA 2535/4885SMN1; SMN2 2448/4885 |
| US-20230127087-A1 | GLYPICAN-3-SPECIFIC MODIFIED APTAMER AND USE THEREOF | LGALS3, LGALS3BP, GOLGA3 | TK1 1780/4885LMNA 1888/4885SMN1; SMN2 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.